NCT06244355 Studies of Phenotypic and Functional Characteristics of Circulating Neutrophil Subpopulations in Patients With Lung Cancer
| NCT ID | NCT06244355 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-02-12 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-02-12 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective is to study the phenotypic, functional and metabolomic characteristics of neutrophils circulating subpopulations in lung cancer patients, and to compare them to a control group of healthy volunteers. A blood sample will be taken before the first treatment session for the lung cancer patient and a second blood sample will be taken during the first evaluation visit. The investigators hypothesize that there may be different circulating neutrophil subpopulations in patients with metastatic non-small cell lung cancer (NSCLC) involved in tumor progression and resistance to immunotherapy.
Eligibility Criteria
Inclusion Criteria common to lung cancer and COPD patients : * Age ≥ 18 years, * male or female, * affiliated with a Health Insurance, Inclusion Criteria for lung cancer patients : \- Diagnosis of metastatic stage lung cancer with mutation status, naïve treatment Inclusion Criteria for COPD patients : \- Diagnosis of COPD post-smoking Exclusion Criteria: * Tuberculosis or other acute or chronic bacterial infections * Chronic progressive viral infections (Hepatitis B and C, HIV) * Previous or ongoing chemotherapy * Impossibility of giving the subject informed information. * Opposition to the research. * Participation in another research study with an exclusion period still in progress at pre-inclusion (possible inclusion in an observational study) * Vulnerable individual (pregnant, parturient or breastfeeding woman), persons under guardianship or curatorship, or deprived of liberty by a judicial or administrative decision) * Patients benefiting from the AME
Contact & Investigator
Marie WISLEZ, Pr
PRINCIPAL INVESTIGATOR
Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
Frequently Asked Questions
Who can join the NCT06244355 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06244355 currently recruiting?
Yes, NCT06244355 is actively recruiting participants. Contact the research team at marie.wislez@aphp.fr for enrollment information.
Where is the NCT06244355 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06244355 clinical trial?
NCT06244355 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Marie WISLEZ, Pr at Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP). The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.